跳至主要内容
临床试验/NCT00699699
NCT00699699已完成不适用

Assessment of Physical Activity (PF10 Sub Domain of SF-36 Activity Score) and Tolerability in COPD Patients During Treatment With Spiriva® Respimat®

Boehringer Ingelheim9 个研究点 分布在 1 个国家目标入组 1,280 人开始时间: 2008年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,280
试验地点
9
主要终点
Therapeutic Success as Change From Baseline in Physical Functioning After 6 Weeks

研究概览

简要总结

This observational non-interventional study is designed to demonstrate the improvement of physical function in COPD patients on treatment with Spiriva Respimat and allows adverse events to be recorded and evaluated.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • COPD patients who require treatment with longacting anticholinergic

排除标准

  • Patients cannot be recruited if any of the general or specific contraindications listed in the Patient information leaflet or the Summary of Product Characteristics applies. Spiriva® Respimat® is contraindicated in patients with hypersensitivity to tiotropium bromide, atropine or its derivatives, e.g. ipratropium or oxitropium or to any of the excipients.

结局指标

主要结局

Therapeutic Success as Change From Baseline in Physical Functioning After 6 Weeks

时间窗: Baseline and after 6 weeks of treatment

Main efficacy measure was therapeutic success rate defined as an improvement from baseline after 6 weeks by at least 10 score points in the PF-10 (subdomain of SF-36) score (range from 0 to 100, 0 reflects worst and 100 best condition)

次要结局

  • Change From Baseline in the PF-10 Score After 6 Weeks(Baseline and after 6 weeks of treatment)
  • Change From Baseline After 6 Weeks in Physician's Global Evaluation (PGE) Form Safety(Baseline and after 6 weeks of treatment)
  • Patients' Satisfaction After 6 Weeks of Treatment(6 weeks)

研究者

申办方类型
Industry

研究点 (9)

Loading locations...

相似试验